Europe’s shift to patient evidence: what it means for JCA and rare-disease sponsors
What is changing in Europe’s approach to patient evidence? Recent guidance, including the EMA Reflection Paper on[…]
EU JCA 2025 Explained: What Rare Disease Sponsors Need to Know Now
The EU Joint Clinical Assessment (JCA) is one of the most significant changes to hit market access in years.[…]